Plasma P‐tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline

Documenti analoghi

• Associations of hippocampal volumes, brain hypometabolism, and plasma NfL with amyloid, tau, and cognitive decline
  di: Feng‐Feng Pan, et al.
  Pubblicazione: (2025)
• Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI
  di: Pashtun Shahim, et al.
  Pubblicazione: (2024)
• Combined use of plasma p‐tau217, NfL, and GFAP predicts domain‐specific cognitive decline in cognitively unimpaired and MCI individuals
  di: Chao‐Yi Wu, et al.
  Pubblicazione: (2025)
• Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic
  di: Dhamidhu Eratne, et al.
  Pubblicazione: (2025)
• Impaired glymphatic function exacerbates tau propagation and the effect of tau pathology on cognitive decline in Alzheimer's disease
  di: Ying Luan, et al.
  Pubblicazione: (2025)